MNPR Q3 Earnings Preview: Revenue Estimate Is 0 USD
Monopar Therapeutics is scheduled to report Q3'26 results on November 06; the report time is not specified. Revenue is estimated at 0 USD, with EPS anticipated at (0.82) USD.
Related stories
Viatris Commences Tender Offer to Acquire Pacira BioSciences
M impact | EQUITY | Oct 30, 2026, 01:03 PM UTC
LyondellBasell Reports Higher Third-Quarter Revenue, Warns Middle East Recovery Will Be Slow
LyondellBasell reported higher quarterly revenue and said Middle East conditions will likely remain fluid. The body is truncated before details on a potential return to pre-conflic
M impact | EQUITY | Oct 30, 2026, 12:59 PM UTC
JPMorgan Downgrades Coursera to Neutral, Cuts Target to $5
JPMorgan lowered its price target from $8 to $5. The new target implies 7.3% upside from Coursera’s Oct. 29 close of $4.66.
M impact | EQUITY | Oct 30, 2026, 12:56 PM UTC
BofA Downgrades Intel to Neutral, Cuts Price Target to $100
BofA lowered its rating on Intel from Buy to Neutral and reduced its price target from $145 to $100.
M impact | EQUITY | Oct 30, 2026, 12:33 PM UTC
Regeneron Shares Rise More Than 8% Premarket After Q3 Earnings Beat
Regeneron reported stronger-than-expected third-quarter earnings, supported by demand for its eye treatments and higher collaboration revenue from Sanofi. Shares gained more than 8
M impact | EQUITY | Oct 30, 2026, 12:31 PM UTC
European session market picture: S&P 500 -1.1%, Nasdaq 100 -2.59%; EUR/USD +0.1%, WTI +1.86%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 1.1 percent, Nasdaq futures is down 2.59 percent, Dow futures is down 0.1 percent and Russell futures is
M impact | EQUITY | Oct 30, 2026, 12:30 PM UTC